NASD · Healthcare · Diagnostics & Research · USA
BioAffinity Technologies Inc is a micro cap company (market value under $300 million) in the Diagnostics & Research industry.
BioAffinity Technologies creates diagnostic tests using flow cytometry and machine learning to identify early-stage lung cancer from patient samples. Its CyPath® Lung test helps physicians assess patients at high risk for lung cancer by detecting cancer-related cells. The company also develops companion diagnostics for asthma and chronic obstructive pulmonary disease, and researches cancer therapies through OncoSelect® Therapeutics.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the BioAffinity Technologies Inc stock.
Slightly undervalued: intrinsic value $2.13 per share, market price $1.93, margin of safety 9.6% (as of 2026-11-17).
Its liquidation floor, current assets minus every liability, values the shares at $2.13; the price of $1.93 is 10% below that value.
All 44 Diagnostics & Research stocks
BIAF is slightly undervalued (as of the 2026-11-17 close). Its liquidation floor, current assets minus every liability, values the shares at $2.13; the price of $1.93 is 10% below that value.
$2.13 per share (as of the 2026-11-17 close), against a market price of $1.93. That is a margin of safety of 9.6%. The value comes from the one valuation method that applies to this company, recomputed every night after the US close.